nodes	percent_of_prediction	percent_of_DWPC	metapath
Flavoxate—Raloxifene—breast cancer	0.506	1	CrCtD
Flavoxate—PDE4D—breast cancer	0.176	1	CbGaD
Flavoxate—Dyclonine—Raloxifene—breast cancer	0.169	0.752	CrCrCtD
Flavoxate—Cloperastine—Raloxifene—breast cancer	0.0557	0.248	CrCrCtD
Flavoxate—PDE8A—mammary gland—breast cancer	0.00124	0.0627	CbGeAlD
Flavoxate—PDE8A—nipple—breast cancer	0.00102	0.0518	CbGeAlD
Flavoxate—PDE4A—mammary gland—breast cancer	0.000991	0.0502	CbGeAlD
Flavoxate—PDE7A—female reproductive system—breast cancer	0.000817	0.0414	CbGeAlD
Flavoxate—PDE7B—adipose tissue—breast cancer	0.000777	0.0394	CbGeAlD
Flavoxate—PDE7B—adrenal gland—breast cancer	0.000697	0.0353	CbGeAlD
Flavoxate—PDE7A—endocrine gland—breast cancer	0.000691	0.035	CbGeAlD
Flavoxate—PDE8B—uterus—breast cancer	0.000632	0.0321	CbGeAlD
Flavoxate—PDE8B—adipose tissue—breast cancer	0.000618	0.0314	CbGeAlD
Flavoxate—PDE8A—endometrium—breast cancer	0.000617	0.0313	CbGeAlD
Flavoxate—Dyclonine—SCN10A—breast cancer	0.0006	0.347	CrCbGaD
Flavoxate—PDE8A—uterus—breast cancer	0.000569	0.0288	CbGeAlD
Flavoxate—PDE8B—female reproductive system—breast cancer	0.000568	0.0288	CbGeAlD
Flavoxate—PDE8A—pituitary gland—breast cancer	0.000559	0.0283	CbGeAlD
Flavoxate—PDE8A—adipose tissue—breast cancer	0.000556	0.0282	CbGeAlD
Flavoxate—PDE8B—adrenal gland—breast cancer	0.000555	0.0281	CbGeAlD
Flavoxate—PDE4D—adipose tissue—breast cancer	0.000504	0.0256	CbGeAlD
Flavoxate—PDE8A—adrenal gland—breast cancer	0.000499	0.0253	CbGeAlD
Flavoxate—PDE4B—nipple—breast cancer	0.000489	0.0248	CbGeAlD
Flavoxate—PDE8B—endocrine gland—breast cancer	0.000481	0.0244	CbGeAlD
Flavoxate—PDE8A—female gonad—breast cancer	0.000465	0.0236	CbGeAlD
Flavoxate—PDE4D—adrenal gland—breast cancer	0.000452	0.0229	CbGeAlD
Flavoxate—PDE4A—adipose tissue—breast cancer	0.000446	0.0226	CbGeAlD
Flavoxate—PDE4D—female gonad—breast cancer	0.000422	0.0214	CbGeAlD
Flavoxate—PDE7B—lymph node—breast cancer	0.000418	0.0212	CbGeAlD
Flavoxate—PDE4A—adrenal gland—breast cancer	0.0004	0.0203	CbGeAlD
Flavoxate—PDE4A—female gonad—breast cancer	0.000373	0.0189	CbGeAlD
Flavoxate—PDE8B—lymph node—breast cancer	0.000333	0.0169	CbGeAlD
Flavoxate—PDE8A—lymph node—breast cancer	0.000299	0.0152	CbGeAlD
Flavoxate—PDE4B—endometrium—breast cancer	0.000295	0.015	CbGeAlD
Flavoxate—Raloxifene—ESR2—breast cancer	0.000285	0.165	CrCbGaD
Flavoxate—PDE4D—lymph node—breast cancer	0.000271	0.0137	CbGeAlD
Flavoxate—PDE4B—pituitary gland—breast cancer	0.000267	0.0135	CbGeAlD
Flavoxate—PDE4B—adipose tissue—breast cancer	0.000266	0.0135	CbGeAlD
Flavoxate—Antrafenine—PTGS1—breast cancer	0.000248	0.143	CrCbGaD
Flavoxate—PDE4B—female reproductive system—breast cancer	0.000244	0.0124	CbGeAlD
Flavoxate—Tension—Letrozole—breast cancer	0.000241	0.00814	CcSEcCtD
Flavoxate—Tension—Anastrozole—breast cancer	0.000241	0.00814	CcSEcCtD
Flavoxate—PDE4A—lymph node—breast cancer	0.00024	0.0122	CbGeAlD
Flavoxate—Nervousness—Anastrozole—breast cancer	0.000239	0.00805	CcSEcCtD
Flavoxate—Nervousness—Letrozole—breast cancer	0.000239	0.00805	CcSEcCtD
Flavoxate—PDE4B—adrenal gland—breast cancer	0.000239	0.0121	CbGeAlD
Flavoxate—Nausea—Fluoxymesterone—breast cancer	0.000237	0.00798	CcSEcCtD
Flavoxate—Leukopenia—Ixabepilone—breast cancer	0.000234	0.00788	CcSEcCtD
Flavoxate—Vision blurred—Letrozole—breast cancer	0.000232	0.00781	CcSEcCtD
Flavoxate—PDE4B—bone marrow—breast cancer	0.000231	0.0117	CbGeAlD
Flavoxate—Confusional state—Exemestane—breast cancer	0.000228	0.00768	CcSEcCtD
Flavoxate—PDE4B—female gonad—breast cancer	0.000222	0.0113	CbGeAlD
Flavoxate—Vertigo—Letrozole—breast cancer	0.000221	0.00745	CcSEcCtD
Flavoxate—CHRM1—female reproductive system—breast cancer	0.000221	0.0112	CbGeAlD
Flavoxate—Leukopenia—Anastrozole—breast cancer	0.00022	0.00742	CcSEcCtD
Flavoxate—Leukopenia—Letrozole—breast cancer	0.00022	0.00742	CcSEcCtD
Flavoxate—Skin disorder—Exemestane—breast cancer	0.00022	0.0074	CcSEcCtD
Flavoxate—Palpitations—Letrozole—breast cancer	0.000217	0.00733	CcSEcCtD
Flavoxate—Vertigo—Raloxifene—breast cancer	0.00021	0.00707	CcSEcCtD
Flavoxate—Leukopenia—Idarubicin—breast cancer	0.000209	0.00704	CcSEcCtD
Flavoxate—Skin disorder—Ixabepilone—breast cancer	0.000207	0.00698	CcSEcCtD
Flavoxate—PDE4B—endocrine gland—breast cancer	0.000207	0.0105	CbGeAlD
Flavoxate—Urticaria—Fulvestrant—breast cancer	0.000207	0.00696	CcSEcCtD
Flavoxate—Drowsiness—Goserelin—breast cancer	0.000206	0.00693	CcSEcCtD
Flavoxate—CHRM2—endocrine gland—breast cancer	0.000205	0.0104	CbGeAlD
Flavoxate—Dry mouth—Letrozole—breast cancer	0.000205	0.0069	CcSEcCtD
Flavoxate—Dry mouth—Anastrozole—breast cancer	0.000205	0.0069	CcSEcCtD
Flavoxate—Confusional state—Anastrozole—breast cancer	0.000202	0.00682	CcSEcCtD
Flavoxate—Tachycardia—Letrozole—breast cancer	0.000196	0.0066	CcSEcCtD
Flavoxate—Skin disorder—Letrozole—breast cancer	0.000195	0.00657	CcSEcCtD
Flavoxate—Raloxifene—CYP19A1—breast cancer	0.000191	0.11	CrCbGaD
Flavoxate—CHRM1—endocrine gland—breast cancer	0.000187	0.00948	CbGeAlD
Flavoxate—Feeling abnormal—Exemestane—breast cancer	0.000186	0.00628	CcSEcCtD
Flavoxate—Skin disorder—Raloxifene—breast cancer	0.000185	0.00624	CcSEcCtD
Flavoxate—Skin disorder—Idarubicin—breast cancer	0.000185	0.00624	CcSEcCtD
Flavoxate—Vomiting—Lapatinib—breast cancer	0.00018	0.00606	CcSEcCtD
Flavoxate—Urticaria—Exemestane—breast cancer	0.00018	0.00605	CcSEcCtD
Flavoxate—Somnolence—Letrozole—breast cancer	0.000179	0.00601	CcSEcCtD
Flavoxate—Somnolence—Anastrozole—breast cancer	0.000179	0.00601	CcSEcCtD
Flavoxate—Headache—Lapatinib—breast cancer	0.000177	0.00597	CcSEcCtD
Flavoxate—Raloxifene—ESR1—breast cancer	0.000176	0.102	CrCbGaD
Flavoxate—Leukopenia—Chlorambucil—breast cancer	0.000169	0.0057	CcSEcCtD
Flavoxate—Nausea—Lapatinib—breast cancer	0.000168	0.00566	CcSEcCtD
Flavoxate—Feeling abnormal—Letrozole—breast cancer	0.000165	0.00558	CcSEcCtD
Flavoxate—Feeling abnormal—Anastrozole—breast cancer	0.000165	0.00558	CcSEcCtD
Flavoxate—Vomiting—Fulvestrant—breast cancer	0.000165	0.00557	CcSEcCtD
Flavoxate—Vomiting—Toremifene—breast cancer	0.000163	0.0055	CcSEcCtD
Flavoxate—Headache—Fulvestrant—breast cancer	0.000163	0.00549	CcSEcCtD
Flavoxate—Eosinophilia—Fluorouracil—breast cancer	0.000162	0.00545	CcSEcCtD
Flavoxate—Headache—Toremifene—breast cancer	0.000161	0.00542	CcSEcCtD
Flavoxate—Urticaria—Anastrozole—breast cancer	0.00016	0.00538	CcSEcCtD
Flavoxate—Urticaria—Letrozole—breast cancer	0.00016	0.00538	CcSEcCtD
Flavoxate—Tension—Goserelin—breast cancer	0.000158	0.00532	CcSEcCtD
Flavoxate—Nervousness—Goserelin—breast cancer	0.000156	0.00526	CcSEcCtD
Flavoxate—Vertigo—Vinblastine—breast cancer	0.000156	0.00525	CcSEcCtD
Flavoxate—Confusional state—Chlorambucil—breast cancer	0.000156	0.00524	CcSEcCtD
Flavoxate—Leukopenia—Vinblastine—breast cancer	0.000155	0.00523	CcSEcCtD
Flavoxate—Nausea—Fulvestrant—breast cancer	0.000155	0.00521	CcSEcCtD
Flavoxate—Nausea—Toremifene—breast cancer	0.000153	0.00514	CcSEcCtD
Flavoxate—Drowsiness—Mitoxantrone—breast cancer	0.000152	0.00512	CcSEcCtD
Flavoxate—Vision blurred—Goserelin—breast cancer	0.000152	0.00511	CcSEcCtD
Flavoxate—Urticaria—Idarubicin—breast cancer	0.000151	0.0051	CcSEcCtD
Flavoxate—Leukopenia—Tamoxifen—breast cancer	0.000151	0.00508	CcSEcCtD
Flavoxate—Leukopenia—Melphalan—breast cancer	0.000148	0.00497	CcSEcCtD
Flavoxate—Leukopenia—Goserelin—breast cancer	0.000144	0.00485	CcSEcCtD
Flavoxate—Vomiting—Exemestane—breast cancer	0.000144	0.00484	CcSEcCtD
Flavoxate—PDE4B—lymph node—breast cancer	0.000143	0.00725	CbGeAlD
Flavoxate—Palpitations—Goserelin—breast cancer	0.000142	0.00479	CcSEcCtD
Flavoxate—Antrafenine—PTGS2—breast cancer	0.000142	0.0818	CrCbGaD
Flavoxate—Headache—Exemestane—breast cancer	0.000142	0.00477	CcSEcCtD
Flavoxate—Dry mouth—Tamoxifen—breast cancer	0.00014	0.00472	CcSEcCtD
Flavoxate—Vomiting—Ixabepilone—breast cancer	0.000136	0.00457	CcSEcCtD
Flavoxate—Tension—Thiotepa—breast cancer	0.000135	0.00455	CcSEcCtD
Flavoxate—Nausea—Exemestane—breast cancer	0.000134	0.00452	CcSEcCtD
Flavoxate—Dry mouth—Goserelin—breast cancer	0.000134	0.00451	CcSEcCtD
Flavoxate—Nervousness—Thiotepa—breast cancer	0.000134	0.0045	CcSEcCtD
Flavoxate—Headache—Ixabepilone—breast cancer	0.000134	0.0045	CcSEcCtD
Flavoxate—Confusional state—Goserelin—breast cancer	0.000132	0.00446	CcSEcCtD
Flavoxate—Tachycardia—Melphalan—breast cancer	0.000131	0.00442	CcSEcCtD
Flavoxate—Skin disorder—Melphalan—breast cancer	0.000131	0.0044	CcSEcCtD
Flavoxate—Vision blurred—Thiotepa—breast cancer	0.00013	0.00437	CcSEcCtD
Flavoxate—Vertigo—Vinorelbine—breast cancer	0.000129	0.00436	CcSEcCtD
Flavoxate—Leukopenia—Vinorelbine—breast cancer	0.000129	0.00434	CcSEcCtD
Flavoxate—Tachycardia—Goserelin—breast cancer	0.000128	0.00432	CcSEcCtD
Flavoxate—Vomiting—Letrozole—breast cancer	0.000128	0.0043	CcSEcCtD
Flavoxate—Vomiting—Anastrozole—breast cancer	0.000128	0.0043	CcSEcCtD
Flavoxate—Skin disorder—Goserelin—breast cancer	0.000127	0.0043	CcSEcCtD
Flavoxate—Palpitations—Vinorelbine—breast cancer	0.000127	0.00429	CcSEcCtD
Flavoxate—Feeling abnormal—Chlorambucil—breast cancer	0.000127	0.00429	CcSEcCtD
Flavoxate—Nausea—Ixabepilone—breast cancer	0.000127	0.00427	CcSEcCtD
Flavoxate—Headache—Anastrozole—breast cancer	0.000126	0.00424	CcSEcCtD
Flavoxate—Headache—Letrozole—breast cancer	0.000126	0.00424	CcSEcCtD
Flavoxate—Leukopenia—Thiotepa—breast cancer	0.000123	0.00415	CcSEcCtD
Flavoxate—Urticaria—Chlorambucil—breast cancer	0.000123	0.00413	CcSEcCtD
Flavoxate—Vomiting—Raloxifene—breast cancer	0.000121	0.00408	CcSEcCtD
Flavoxate—Vomiting—Idarubicin—breast cancer	0.000121	0.00408	CcSEcCtD
Flavoxate—Headache—Raloxifene—breast cancer	0.000119	0.00402	CcSEcCtD
Flavoxate—Headache—Idarubicin—breast cancer	0.000119	0.00402	CcSEcCtD
Flavoxate—Nausea—Anastrozole—breast cancer	0.000119	0.00402	CcSEcCtD
Flavoxate—Nausea—Letrozole—breast cancer	0.000119	0.00402	CcSEcCtD
Flavoxate—Somnolence—Goserelin—breast cancer	0.000117	0.00393	CcSEcCtD
Flavoxate—Feeling abnormal—Vinblastine—breast cancer	0.000117	0.00393	CcSEcCtD
Flavoxate—Tachycardia—Vinorelbine—breast cancer	0.000115	0.00387	CcSEcCtD
Flavoxate—Skin disorder—Vinorelbine—breast cancer	0.000114	0.00385	CcSEcCtD
Flavoxate—Nausea—Idarubicin—breast cancer	0.000113	0.00381	CcSEcCtD
Flavoxate—Nausea—Raloxifene—breast cancer	0.000113	0.00381	CcSEcCtD
Flavoxate—Confusional state—Thiotepa—breast cancer	0.000113	0.00381	CcSEcCtD
Flavoxate—Vision blurred—Mitoxantrone—breast cancer	0.000112	0.00377	CcSEcCtD
Flavoxate—Tachycardia—Thiotepa—breast cancer	0.00011	0.00369	CcSEcCtD
Flavoxate—Urticaria—Tamoxifen—breast cancer	0.000109	0.00368	CcSEcCtD
Flavoxate—Skin disorder—Thiotepa—breast cancer	0.000109	0.00367	CcSEcCtD
Flavoxate—Feeling abnormal—Goserelin—breast cancer	0.000108	0.00364	CcSEcCtD
Flavoxate—Vision blurred—Fluorouracil—breast cancer	0.000107	0.00361	CcSEcCtD
Flavoxate—Urticaria—Melphalan—breast cancer	0.000107	0.0036	CcSEcCtD
Flavoxate—Vertigo—Irinotecan—breast cancer	0.000107	0.0036	CcSEcCtD
Flavoxate—Leukopenia—Irinotecan—breast cancer	0.000106	0.00358	CcSEcCtD
Flavoxate—Leukopenia—Mitoxantrone—breast cancer	0.000106	0.00358	CcSEcCtD
Flavoxate—Urticaria—Goserelin—breast cancer	0.000104	0.00351	CcSEcCtD
Flavoxate—Leukopenia—Gemcitabine—breast cancer	0.000104	0.00349	CcSEcCtD
Flavoxate—Leukopenia—Fluorouracil—breast cancer	0.000102	0.00343	CcSEcCtD
Flavoxate—Somnolence—Thiotepa—breast cancer	9.98e-05	0.00336	CcSEcCtD
Flavoxate—Vomiting—Chlorambucil—breast cancer	9.81e-05	0.00331	CcSEcCtD
Flavoxate—Confusional state—Mitoxantrone—breast cancer	9.77e-05	0.00329	CcSEcCtD
Flavoxate—Confusional state—Irinotecan—breast cancer	9.77e-05	0.00329	CcSEcCtD
Flavoxate—Feeling abnormal—Vinorelbine—breast cancer	9.69e-05	0.00326	CcSEcCtD
Flavoxate—Tension—Paclitaxel—breast cancer	9.51e-05	0.0032	CcSEcCtD
Flavoxate—Tachycardia—Mitoxantrone—breast cancer	9.46e-05	0.00319	CcSEcCtD
Flavoxate—Skin disorder—Mitoxantrone—breast cancer	9.42e-05	0.00317	CcSEcCtD
Flavoxate—Nervousness—Paclitaxel—breast cancer	9.41e-05	0.00317	CcSEcCtD
Flavoxate—Confusional state—Fluorouracil—breast cancer	9.36e-05	0.00315	CcSEcCtD
Flavoxate—Urticaria—Vinorelbine—breast cancer	9.34e-05	0.00315	CcSEcCtD
Flavoxate—Feeling abnormal—Thiotepa—breast cancer	9.25e-05	0.00312	CcSEcCtD
Flavoxate—Skin disorder—Gemcitabine—breast cancer	9.17e-05	0.00309	CcSEcCtD
Flavoxate—Nausea—Chlorambucil—breast cancer	9.17e-05	0.00309	CcSEcCtD
Flavoxate—Vision blurred—Paclitaxel—breast cancer	9.13e-05	0.00308	CcSEcCtD
Flavoxate—Tachycardia—Fluorouracil—breast cancer	9.06e-05	0.00305	CcSEcCtD
Flavoxate—Vomiting—Vinblastine—breast cancer	8.99e-05	0.00303	CcSEcCtD
Flavoxate—Raloxifene—CYP3A4—breast cancer	8.97e-05	0.0518	CrCbGaD
Flavoxate—Urticaria—Thiotepa—breast cancer	8.92e-05	0.003	CcSEcCtD
Flavoxate—Headache—Vinblastine—breast cancer	8.86e-05	0.00299	CcSEcCtD
Flavoxate—Vomiting—Tamoxifen—breast cancer	8.74e-05	0.00294	CcSEcCtD
Flavoxate—Vertigo—Paclitaxel—breast cancer	8.7e-05	0.00293	CcSEcCtD
Flavoxate—Leukopenia—Paclitaxel—breast cancer	8.67e-05	0.00292	CcSEcCtD
Flavoxate—Somnolence—Mitoxantrone—breast cancer	8.62e-05	0.0029	CcSEcCtD
Flavoxate—Somnolence—Irinotecan—breast cancer	8.62e-05	0.0029	CcSEcCtD
Flavoxate—Headache—Tamoxifen—breast cancer	8.61e-05	0.0029	CcSEcCtD
Flavoxate—Palpitations—Paclitaxel—breast cancer	8.56e-05	0.00288	CcSEcCtD
Flavoxate—Vomiting—Melphalan—breast cancer	8.55e-05	0.00288	CcSEcCtD
Flavoxate—Eosinophilia—Methotrexate—breast cancer	8.41e-05	0.00283	CcSEcCtD
Flavoxate—Nausea—Vinblastine—breast cancer	8.4e-05	0.00283	CcSEcCtD
Flavoxate—Somnolence—Gemcitabine—breast cancer	8.4e-05	0.00283	CcSEcCtD
Flavoxate—Vomiting—Goserelin—breast cancer	8.34e-05	0.00281	CcSEcCtD
Flavoxate—Somnolence—Fluorouracil—breast cancer	8.25e-05	0.00278	CcSEcCtD
Flavoxate—Headache—Goserelin—breast cancer	8.22e-05	0.00277	CcSEcCtD
Flavoxate—Nausea—Tamoxifen—breast cancer	8.16e-05	0.00275	CcSEcCtD
Flavoxate—Dry mouth—Paclitaxel—breast cancer	8.07e-05	0.00272	CcSEcCtD
Flavoxate—Nausea—Melphalan—breast cancer	7.99e-05	0.00269	CcSEcCtD
Flavoxate—Feeling abnormal—Mitoxantrone—breast cancer	7.99e-05	0.00269	CcSEcCtD
Flavoxate—Feeling abnormal—Irinotecan—breast cancer	7.99e-05	0.00269	CcSEcCtD
Flavoxate—Confusional state—Paclitaxel—breast cancer	7.97e-05	0.00269	CcSEcCtD
Flavoxate—Eosinophilia—Epirubicin—breast cancer	7.87e-05	0.00265	CcSEcCtD
Flavoxate—Nausea—Goserelin—breast cancer	7.8e-05	0.00263	CcSEcCtD
Flavoxate—Feeling abnormal—Gemcitabine—breast cancer	7.78e-05	0.00262	CcSEcCtD
Flavoxate—Tachycardia—Paclitaxel—breast cancer	7.72e-05	0.0026	CcSEcCtD
Flavoxate—Urticaria—Mitoxantrone—breast cancer	7.7e-05	0.0026	CcSEcCtD
Flavoxate—Skin disorder—Paclitaxel—breast cancer	7.68e-05	0.00259	CcSEcCtD
Flavoxate—Feeling abnormal—Fluorouracil—breast cancer	7.65e-05	0.00258	CcSEcCtD
Flavoxate—Drowsiness—Methotrexate—breast cancer	7.57e-05	0.00255	CcSEcCtD
Flavoxate—Vision blurred—Capecitabine—breast cancer	7.49e-05	0.00252	CcSEcCtD
Flavoxate—Vomiting—Vinorelbine—breast cancer	7.47e-05	0.00252	CcSEcCtD
Flavoxate—Urticaria—Fluorouracil—breast cancer	7.38e-05	0.00249	CcSEcCtD
Flavoxate—Headache—Vinorelbine—breast cancer	7.36e-05	0.00248	CcSEcCtD
Flavoxate—Leukopenia—Docetaxel—breast cancer	7.35e-05	0.00248	CcSEcCtD
Flavoxate—Eosinophilia—Doxorubicin—breast cancer	7.28e-05	0.00245	CcSEcCtD
Flavoxate—Palpitations—Docetaxel—breast cancer	7.26e-05	0.00245	CcSEcCtD
Flavoxate—Vertigo—Capecitabine—breast cancer	7.14e-05	0.00241	CcSEcCtD
Flavoxate—Vomiting—Thiotepa—breast cancer	7.14e-05	0.00241	CcSEcCtD
Flavoxate—Leukopenia—Capecitabine—breast cancer	7.12e-05	0.0024	CcSEcCtD
Flavoxate—Drowsiness—Epirubicin—breast cancer	7.09e-05	0.00239	CcSEcCtD
Flavoxate—Headache—Thiotepa—breast cancer	7.03e-05	0.00237	CcSEcCtD
Flavoxate—Somnolence—Paclitaxel—breast cancer	7.03e-05	0.00237	CcSEcCtD
Flavoxate—Palpitations—Capecitabine—breast cancer	7.03e-05	0.00237	CcSEcCtD
Flavoxate—Nausea—Vinorelbine—breast cancer	6.98e-05	0.00235	CcSEcCtD
Flavoxate—Dry mouth—Docetaxel—breast cancer	6.84e-05	0.0023	CcSEcCtD
Flavoxate—Confusional state—Docetaxel—breast cancer	6.76e-05	0.00228	CcSEcCtD
Flavoxate—Nausea—Thiotepa—breast cancer	6.67e-05	0.00225	CcSEcCtD
Flavoxate—Dry mouth—Capecitabine—breast cancer	6.62e-05	0.00223	CcSEcCtD
Flavoxate—Drowsiness—Doxorubicin—breast cancer	6.56e-05	0.00221	CcSEcCtD
Flavoxate—Confusional state—Capecitabine—breast cancer	6.54e-05	0.0022	CcSEcCtD
Flavoxate—Tachycardia—Docetaxel—breast cancer	6.54e-05	0.0022	CcSEcCtD
Flavoxate—Feeling abnormal—Paclitaxel—breast cancer	6.52e-05	0.0022	CcSEcCtD
Flavoxate—Skin disorder—Docetaxel—breast cancer	6.51e-05	0.00219	CcSEcCtD
Flavoxate—Tachycardia—Capecitabine—breast cancer	6.33e-05	0.00213	CcSEcCtD
Flavoxate—Skin disorder—Capecitabine—breast cancer	6.3e-05	0.00212	CcSEcCtD
Flavoxate—Urticaria—Paclitaxel—breast cancer	6.28e-05	0.00212	CcSEcCtD
Flavoxate—Vomiting—Irinotecan—breast cancer	6.16e-05	0.00208	CcSEcCtD
Flavoxate—Vomiting—Mitoxantrone—breast cancer	6.16e-05	0.00208	CcSEcCtD
Flavoxate—Headache—Mitoxantrone—breast cancer	6.07e-05	0.00205	CcSEcCtD
Flavoxate—Headache—Irinotecan—breast cancer	6.07e-05	0.00205	CcSEcCtD
Flavoxate—Vomiting—Gemcitabine—breast cancer	6e-05	0.00202	CcSEcCtD
Flavoxate—Somnolence—Docetaxel—breast cancer	5.96e-05	0.00201	CcSEcCtD
Flavoxate—Headache—Gemcitabine—breast cancer	5.92e-05	0.00199	CcSEcCtD
Flavoxate—Vomiting—Fluorouracil—breast cancer	5.9e-05	0.00199	CcSEcCtD
Flavoxate—Headache—Fluorouracil—breast cancer	5.82e-05	0.00196	CcSEcCtD
Flavoxate—Nausea—Irinotecan—breast cancer	5.76e-05	0.00194	CcSEcCtD
Flavoxate—Nausea—Mitoxantrone—breast cancer	5.76e-05	0.00194	CcSEcCtD
Flavoxate—Nausea—Gemcitabine—breast cancer	5.61e-05	0.00189	CcSEcCtD
Flavoxate—Vision blurred—Methotrexate—breast cancer	5.58e-05	0.00188	CcSEcCtD
Flavoxate—Feeling abnormal—Docetaxel—breast cancer	5.52e-05	0.00186	CcSEcCtD
Flavoxate—Nausea—Fluorouracil—breast cancer	5.52e-05	0.00186	CcSEcCtD
Flavoxate—Tension—Epirubicin—breast cancer	5.43e-05	0.00183	CcSEcCtD
Flavoxate—Nervousness—Epirubicin—breast cancer	5.38e-05	0.00181	CcSEcCtD
Flavoxate—Feeling abnormal—Capecitabine—breast cancer	5.35e-05	0.0018	CcSEcCtD
Flavoxate—Vertigo—Methotrexate—breast cancer	5.32e-05	0.00179	CcSEcCtD
Flavoxate—Leukopenia—Methotrexate—breast cancer	5.3e-05	0.00179	CcSEcCtD
Flavoxate—Vision blurred—Epirubicin—breast cancer	5.22e-05	0.00176	CcSEcCtD
Flavoxate—Urticaria—Capecitabine—breast cancer	5.15e-05	0.00174	CcSEcCtD
Flavoxate—Tension—Doxorubicin—breast cancer	5.03e-05	0.00169	CcSEcCtD
Flavoxate—Vomiting—Paclitaxel—breast cancer	5.03e-05	0.00169	CcSEcCtD
Flavoxate—Nervousness—Doxorubicin—breast cancer	4.98e-05	0.00168	CcSEcCtD
Flavoxate—Vertigo—Epirubicin—breast cancer	4.98e-05	0.00168	CcSEcCtD
Flavoxate—Leukopenia—Epirubicin—breast cancer	4.96e-05	0.00167	CcSEcCtD
Flavoxate—Headache—Paclitaxel—breast cancer	4.95e-05	0.00167	CcSEcCtD
Flavoxate—Palpitations—Epirubicin—breast cancer	4.89e-05	0.00165	CcSEcCtD
Flavoxate—Confusional state—Methotrexate—breast cancer	4.87e-05	0.00164	CcSEcCtD
Flavoxate—Vision blurred—Doxorubicin—breast cancer	4.83e-05	0.00163	CcSEcCtD
Flavoxate—Nausea—Paclitaxel—breast cancer	4.7e-05	0.00158	CcSEcCtD
Flavoxate—Skin disorder—Methotrexate—breast cancer	4.69e-05	0.00158	CcSEcCtD
Flavoxate—Dry mouth—Epirubicin—breast cancer	4.61e-05	0.00155	CcSEcCtD
Flavoxate—Vertigo—Doxorubicin—breast cancer	4.6e-05	0.00155	CcSEcCtD
Flavoxate—Leukopenia—Doxorubicin—breast cancer	4.59e-05	0.00155	CcSEcCtD
Flavoxate—Confusional state—Epirubicin—breast cancer	4.56e-05	0.00154	CcSEcCtD
Flavoxate—Palpitations—Doxorubicin—breast cancer	4.53e-05	0.00153	CcSEcCtD
Flavoxate—Tachycardia—Epirubicin—breast cancer	4.41e-05	0.00149	CcSEcCtD
Flavoxate—Skin disorder—Epirubicin—breast cancer	4.39e-05	0.00148	CcSEcCtD
Flavoxate—Somnolence—Methotrexate—breast cancer	4.29e-05	0.00145	CcSEcCtD
Flavoxate—Dry mouth—Doxorubicin—breast cancer	4.27e-05	0.00144	CcSEcCtD
Flavoxate—Vomiting—Docetaxel—breast cancer	4.26e-05	0.00144	CcSEcCtD
Flavoxate—Confusional state—Doxorubicin—breast cancer	4.22e-05	0.00142	CcSEcCtD
Flavoxate—Headache—Docetaxel—breast cancer	4.2e-05	0.00141	CcSEcCtD
Flavoxate—Vomiting—Capecitabine—breast cancer	4.13e-05	0.00139	CcSEcCtD
Flavoxate—Tachycardia—Doxorubicin—breast cancer	4.08e-05	0.00138	CcSEcCtD
Flavoxate—Headache—Capecitabine—breast cancer	4.06e-05	0.00137	CcSEcCtD
Flavoxate—Skin disorder—Doxorubicin—breast cancer	4.06e-05	0.00137	CcSEcCtD
Flavoxate—Somnolence—Epirubicin—breast cancer	4.02e-05	0.00135	CcSEcCtD
Flavoxate—Nausea—Docetaxel—breast cancer	3.98e-05	0.00134	CcSEcCtD
Flavoxate—Feeling abnormal—Methotrexate—breast cancer	3.98e-05	0.00134	CcSEcCtD
Flavoxate—Nausea—Capecitabine—breast cancer	3.85e-05	0.0013	CcSEcCtD
Flavoxate—Urticaria—Methotrexate—breast cancer	3.84e-05	0.00129	CcSEcCtD
Flavoxate—Feeling abnormal—Epirubicin—breast cancer	3.72e-05	0.00126	CcSEcCtD
Flavoxate—Somnolence—Doxorubicin—breast cancer	3.72e-05	0.00125	CcSEcCtD
Flavoxate—Urticaria—Epirubicin—breast cancer	3.59e-05	0.00121	CcSEcCtD
Flavoxate—Feeling abnormal—Doxorubicin—breast cancer	3.45e-05	0.00116	CcSEcCtD
Flavoxate—Urticaria—Doxorubicin—breast cancer	3.32e-05	0.00112	CcSEcCtD
Flavoxate—Vomiting—Methotrexate—breast cancer	3.07e-05	0.00103	CcSEcCtD
Flavoxate—Headache—Methotrexate—breast cancer	3.03e-05	0.00102	CcSEcCtD
Flavoxate—Vomiting—Epirubicin—breast cancer	2.87e-05	0.000968	CcSEcCtD
Flavoxate—Nausea—Methotrexate—breast cancer	2.87e-05	0.000967	CcSEcCtD
Flavoxate—Headache—Epirubicin—breast cancer	2.83e-05	0.000954	CcSEcCtD
Flavoxate—Nausea—Epirubicin—breast cancer	2.68e-05	0.000905	CcSEcCtD
Flavoxate—Vomiting—Doxorubicin—breast cancer	2.66e-05	0.000896	CcSEcCtD
Flavoxate—Headache—Doxorubicin—breast cancer	2.62e-05	0.000883	CcSEcCtD
Flavoxate—Nausea—Doxorubicin—breast cancer	2.48e-05	0.000837	CcSEcCtD
Flavoxate—CHRM1—Signaling Pathways—NOTCH2—breast cancer	2.13e-06	5.03e-05	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—CASP3—breast cancer	2.12e-06	5e-05	CbGpPWpGaD
Flavoxate—CHRM1—GPCR downstream signaling—PIK3CD—breast cancer	2.11e-06	4.99e-05	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—IL2—breast cancer	2.11e-06	4.99e-05	CbGpPWpGaD
Flavoxate—PDE4C—Signaling Pathways—EGFR—breast cancer	2.11e-06	4.98e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—NOTCH2—breast cancer	2.1e-06	4.97e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—HSP90AA1—breast cancer	2.1e-06	4.97e-05	CbGpPWpGaD
Flavoxate—PDE4B—Signaling by GPCR—IL6—breast cancer	2.1e-06	4.97e-05	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—MAPK8—breast cancer	2.1e-06	4.96e-05	CbGpPWpGaD
Flavoxate—PDE4A—Signaling by GPCR—AKT1—breast cancer	2.1e-06	4.95e-05	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—SRC—breast cancer	2.09e-06	4.94e-05	CbGpPWpGaD
Flavoxate—CHRM2—GPCR downstream signaling—PIK3CD—breast cancer	2.09e-06	4.93e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—PRL—breast cancer	2.07e-06	4.9e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—AGTR1—breast cancer	2.07e-06	4.9e-05	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—CCND1—breast cancer	2.06e-06	4.87e-05	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—JUN—breast cancer	2.06e-06	4.85e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—PRL—breast cancer	2.05e-06	4.83e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—AGTR1—breast cancer	2.05e-06	4.83e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—STK11—breast cancer	2.04e-06	4.82e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—ADAM10—breast cancer	2.04e-06	4.82e-05	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—CTNNB1—breast cancer	2.04e-06	4.82e-05	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—VEGFA—breast cancer	2.04e-06	4.82e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—PLG—breast cancer	2.02e-06	4.77e-05	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—STAT3—breast cancer	2.02e-06	4.77e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—ADAM10—breast cancer	2.02e-06	4.76e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—STK11—breast cancer	2.02e-06	4.76e-05	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—MMP9—breast cancer	2e-06	4.72e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling by GPCR—AKT2—breast cancer	2e-06	4.72e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—PLG—breast cancer	1.99e-06	4.71e-05	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—CDKN1A—breast cancer	1.99e-06	4.71e-05	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—SRC—breast cancer	1.99e-06	4.71e-05	CbGpPWpGaD
Flavoxate—PDE4C—Signaling Pathways—KRAS—breast cancer	1.99e-06	4.7e-05	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—PTEN—breast cancer	1.99e-06	4.7e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—FGF10—breast cancer	1.99e-06	4.69e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling by GPCR—AKT2—breast cancer	1.97e-06	4.66e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—FGF10—breast cancer	1.96e-06	4.63e-05	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—MAPK8—breast cancer	1.95e-06	4.59e-05	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—VEGFA—breast cancer	1.94e-06	4.58e-05	CbGpPWpGaD
Flavoxate—PDE4B—Signaling by GPCR—AKT1—breast cancer	1.94e-06	4.58e-05	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—MAPK3—breast cancer	1.93e-06	4.56e-05	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—STAT3—breast cancer	1.92e-06	4.54e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling by GPCR—PIK3CD—breast cancer	1.92e-06	4.53e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—PDGFA—breast cancer	1.92e-06	4.53e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling by GPCR—PIK3CD—breast cancer	1.9e-06	4.47e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—PDGFA—breast cancer	1.89e-06	4.47e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—TGFBR2—breast cancer	1.89e-06	4.46e-05	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—MYC—breast cancer	1.88e-06	4.43e-05	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—TGFB1—breast cancer	1.87e-06	4.42e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—TGFBR2—breast cancer	1.87e-06	4.41e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—ITPR1—breast cancer	1.86e-06	4.39e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—STAT5A—breast cancer	1.85e-06	4.36e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—ERBB4—breast cancer	1.85e-06	4.36e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—MMP3—breast cancer	1.85e-06	4.36e-05	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—SRC—breast cancer	1.84e-06	4.35e-05	CbGpPWpGaD
Flavoxate—CHRM1—GPCR downstream signaling—PIK3CB—breast cancer	1.84e-06	4.35e-05	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—MAPK3—breast cancer	1.84e-06	4.34e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—ITPR1—breast cancer	1.84e-06	4.34e-05	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—EGFR—breast cancer	1.84e-06	4.33e-05	CbGpPWpGaD
Flavoxate—PDE4C—Signaling Pathways—PIK3CA—breast cancer	1.83e-06	4.32e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—MMP3—breast cancer	1.82e-06	4.31e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—ERBB4—breast cancer	1.82e-06	4.31e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—STAT5A—breast cancer	1.82e-06	4.31e-05	CbGpPWpGaD
Flavoxate—CHRM2—GPCR downstream signaling—PIK3CB—breast cancer	1.82e-06	4.29e-05	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—VEGFA—breast cancer	1.8e-06	4.24e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—SMAD4—breast cancer	1.79e-06	4.23e-05	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—MYC—breast cancer	1.79e-06	4.22e-05	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—TGFB1—breast cancer	1.78e-06	4.21e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—IGF1R—breast cancer	1.78e-06	4.2e-05	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—STAT3—breast cancer	1.78e-06	4.2e-05	CbGpPWpGaD
Flavoxate—CHRM1—GPCR downstream signaling—CXCL8—breast cancer	1.77e-06	4.18e-05	CbGpPWpGaD
Flavoxate—PDE4C—Signaling Pathways—TP53—breast cancer	1.77e-06	4.18e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—SMAD4—breast cancer	1.77e-06	4.17e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—IGF1R—breast cancer	1.76e-06	4.15e-05	CbGpPWpGaD
Flavoxate—CHRM2—GPCR downstream signaling—CXCL8—breast cancer	1.75e-06	4.13e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—HES1—breast cancer	1.75e-06	4.13e-05	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—EGFR—breast cancer	1.75e-06	4.13e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—PLA2G4A—breast cancer	1.74e-06	4.1e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—NCOR1—breast cancer	1.74e-06	4.1e-05	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—KRAS—breast cancer	1.73e-06	4.09e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—HES1—breast cancer	1.73e-06	4.07e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—FGF1—breast cancer	1.72e-06	4.06e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—CSF2—breast cancer	1.72e-06	4.06e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—NCOR1—breast cancer	1.72e-06	4.05e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—PLA2G4A—breast cancer	1.72e-06	4.05e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling by GPCR—RAF1—breast cancer	1.71e-06	4.05e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—NRG1—breast cancer	1.71e-06	4.03e-05	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—MAPK3—breast cancer	1.7e-06	4.01e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—FGF1—breast cancer	1.7e-06	4e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—CSF2—breast cancer	1.7e-06	4e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—H2AFX—breast cancer	1.69e-06	4e-05	CbGpPWpGaD
Flavoxate—PDE4C—Signaling Pathways—HRAS—breast cancer	1.69e-06	4e-05	CbGpPWpGaD
Flavoxate—CHRM1—GPCR downstream signaling—IL2—breast cancer	1.69e-06	4e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling by GPCR—RAF1—breast cancer	1.69e-06	3.99e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—NRG1—breast cancer	1.68e-06	3.97e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—E2F1—breast cancer	1.68e-06	3.97e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling by GPCR—PIK3CB—breast cancer	1.67e-06	3.95e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—H2AFX—breast cancer	1.67e-06	3.95e-05	CbGpPWpGaD
Flavoxate—CHRM2—GPCR downstream signaling—IL2—breast cancer	1.67e-06	3.94e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—E2F1—breast cancer	1.66e-06	3.92e-05	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—MYC—breast cancer	1.65e-06	3.9e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling by GPCR—PIK3CB—breast cancer	1.65e-06	3.9e-05	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—KRAS—breast cancer	1.65e-06	3.9e-05	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—TGFB1—breast cancer	1.65e-06	3.89e-05	CbGpPWpGaD
Flavoxate—PDE4C—Signaling Pathways—IL6—breast cancer	1.62e-06	3.83e-05	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—EGFR—breast cancer	1.62e-06	3.82e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—SPP1—breast cancer	1.62e-06	3.81e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling by GPCR—CXCL8—breast cancer	1.61e-06	3.8e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—ERBB3—breast cancer	1.6e-06	3.77e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—FGFR2—breast cancer	1.6e-06	3.77e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—SPP1—breast cancer	1.59e-06	3.76e-05	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—PIK3CA—breast cancer	1.59e-06	3.76e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling by GPCR—CXCL8—breast cancer	1.59e-06	3.75e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—ERBB3—breast cancer	1.58e-06	3.72e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—FGFR2—breast cancer	1.57e-06	3.72e-05	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—TP53—breast cancer	1.54e-06	3.64e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling by GPCR—IL2—breast cancer	1.54e-06	3.63e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—TERT—breast cancer	1.53e-06	3.62e-05	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—KRAS—breast cancer	1.53e-06	3.61e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling by GPCR—IL2—breast cancer	1.52e-06	3.58e-05	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—PIK3CA—breast cancer	1.52e-06	3.58e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—TERT—breast cancer	1.51e-06	3.57e-05	CbGpPWpGaD
Flavoxate—PDE4C—Signaling Pathways—AKT1—breast cancer	1.5e-06	3.53e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—FGFR1—breast cancer	1.49e-06	3.51e-05	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—HRAS—breast cancer	1.47e-06	3.48e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—FGFR1—breast cancer	1.47e-06	3.47e-05	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—TP53—breast cancer	1.47e-06	3.46e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—HIF1A—breast cancer	1.46e-06	3.46e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—HIF1A—breast cancer	1.45e-06	3.41e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—LEP—breast cancer	1.43e-06	3.38e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—CAV1—breast cancer	1.42e-06	3.34e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—LEP—breast cancer	1.41e-06	3.33e-05	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—IL6—breast cancer	1.41e-06	3.33e-05	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—PIK3CA—breast cancer	1.4e-06	3.31e-05	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—HRAS—breast cancer	1.4e-06	3.31e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—KDR—breast cancer	1.4e-06	3.31e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—CAV1—breast cancer	1.4e-06	3.3e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—KDR—breast cancer	1.38e-06	3.26e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—ESR1—breast cancer	1.36e-06	3.22e-05	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—TP53—breast cancer	1.36e-06	3.2e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—FN1—breast cancer	1.35e-06	3.18e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—ESR1—breast cancer	1.35e-06	3.18e-05	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—IL6—breast cancer	1.34e-06	3.17e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—NFKBIA—breast cancer	1.33e-06	3.15e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—FN1—breast cancer	1.33e-06	3.14e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—NOTCH1—breast cancer	1.32e-06	3.11e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—NFKBIA—breast cancer	1.32e-06	3.1e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—NOTCH1—breast cancer	1.3e-06	3.07e-05	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—AKT1—breast cancer	1.3e-06	3.07e-05	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—HRAS—breast cancer	1.3e-06	3.06e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—PIK3CG—breast cancer	1.29e-06	3.05e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—APC—breast cancer	1.29e-06	3.05e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—KIT—breast cancer	1.29e-06	3.05e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—EGF—breast cancer	1.28e-06	3.01e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—PIK3CG—breast cancer	1.27e-06	3.01e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—KIT—breast cancer	1.27e-06	3.01e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—APC—breast cancer	1.27e-06	3.01e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—EGF—breast cancer	1.26e-06	2.97e-05	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—IL6—breast cancer	1.24e-06	2.93e-05	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—AKT1—breast cancer	1.24e-06	2.92e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling by GPCR—MAPK3—breast cancer	1.24e-06	2.92e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling by GPCR—MAPK3—breast cancer	1.22e-06	2.88e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—BRAF—breast cancer	1.21e-06	2.86e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—BRAF—breast cancer	1.2e-06	2.83e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—IGF1—breast cancer	1.18e-06	2.79e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—AKT2—breast cancer	1.18e-06	2.79e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling by GPCR—EGFR—breast cancer	1.18e-06	2.78e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—IGF1—breast cancer	1.17e-06	2.75e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—AKT2—breast cancer	1.17e-06	2.75e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling by GPCR—EGFR—breast cancer	1.16e-06	2.74e-05	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—AKT1—breast cancer	1.15e-06	2.71e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—PIK3CD—breast cancer	1.13e-06	2.68e-05	CbGpPWpGaD
Flavoxate—CHRM1—GPCR downstream signaling—PIK3CA—breast cancer	1.12e-06	2.65e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—SERPINE1—breast cancer	1.12e-06	2.65e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—PIK3CD—breast cancer	1.12e-06	2.64e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling by GPCR—KRAS—breast cancer	1.11e-06	2.62e-05	CbGpPWpGaD
Flavoxate—CHRM2—GPCR downstream signaling—PIK3CA—breast cancer	1.11e-06	2.62e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—SERPINE1—breast cancer	1.11e-06	2.61e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling by GPCR—KRAS—breast cancer	1.1e-06	2.59e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—NOS3—breast cancer	1.07e-06	2.53e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—NOS3—breast cancer	1.06e-06	2.5e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling by GPCR—PIK3CA—breast cancer	1.02e-06	2.41e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—MDM2—breast cancer	1.02e-06	2.4e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—RAF1—breast cancer	1.01e-06	2.39e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—RELA—breast cancer	1.01e-06	2.38e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling by GPCR—PIK3CA—breast cancer	1.01e-06	2.38e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—MDM2—breast cancer	1e-06	2.37e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—ERBB2—breast cancer	1e-06	2.37e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—RAF1—breast cancer	1e-06	2.36e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—RELA—breast cancer	9.95e-07	2.35e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—ERBB2—breast cancer	9.89e-07	2.33e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—MTOR—breast cancer	9.89e-07	2.33e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—PIK3CB—breast cancer	9.89e-07	2.33e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—MTOR—breast cancer	9.76e-07	2.3e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—PIK3CB—breast cancer	9.76e-07	2.3e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—CXCL8—breast cancer	9.5e-07	2.24e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling by GPCR—HRAS—breast cancer	9.44e-07	2.23e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—CXCL8—breast cancer	9.38e-07	2.21e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling by GPCR—HRAS—breast cancer	9.32e-07	2.2e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—CDKN1B—breast cancer	9.28e-07	2.19e-05	CbGpPWpGaD
Flavoxate—CHRM1—GPCR downstream signaling—AKT1—breast cancer	9.18e-07	2.17e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—CDKN1B—breast cancer	9.16e-07	2.16e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—CASP3—breast cancer	9.09e-07	2.15e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—IL2—breast cancer	9.08e-07	2.14e-05	CbGpPWpGaD
Flavoxate—CHRM2—GPCR downstream signaling—AKT1—breast cancer	9.06e-07	2.14e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling by GPCR—IL6—breast cancer	9.03e-07	2.13e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—CASP3—breast cancer	8.98e-07	2.12e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—IL2—breast cancer	8.96e-07	2.12e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling by GPCR—IL6—breast cancer	8.92e-07	2.11e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—CCND1—breast cancer	8.85e-07	2.09e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—JUN—breast cancer	8.83e-07	2.09e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—CTNNB1—breast cancer	8.76e-07	2.07e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—CCND1—breast cancer	8.74e-07	2.06e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—JUN—breast cancer	8.72e-07	2.06e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—CTNNB1—breast cancer	8.65e-07	2.04e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—MMP9—breast cancer	8.59e-07	2.03e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—CDKN1A—breast cancer	8.56e-07	2.02e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—PTEN—breast cancer	8.54e-07	2.02e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—MMP9—breast cancer	8.48e-07	2e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—CDKN1A—breast cancer	8.45e-07	2e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—PTEN—breast cancer	8.43e-07	1.99e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—MAPK8—breast cancer	8.36e-07	1.97e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling by GPCR—AKT1—breast cancer	8.33e-07	1.97e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—MAPK8—breast cancer	8.25e-07	1.95e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling by GPCR—AKT1—breast cancer	8.23e-07	1.94e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—SRC—breast cancer	7.92e-07	1.87e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—SRC—breast cancer	7.82e-07	1.85e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—VEGFA—breast cancer	7.72e-07	1.82e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—STAT3—breast cancer	7.64e-07	1.8e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—VEGFA—breast cancer	7.62e-07	1.8e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—STAT3—breast cancer	7.54e-07	1.78e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—MAPK3—breast cancer	7.3e-07	1.72e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—MAPK3—breast cancer	7.21e-07	1.7e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—MYC—breast cancer	7.1e-07	1.68e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—TGFB1—breast cancer	7.08e-07	1.67e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—MYC—breast cancer	7.01e-07	1.65e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—TGFB1—breast cancer	6.99e-07	1.65e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—EGFR—breast cancer	6.94e-07	1.64e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—EGFR—breast cancer	6.85e-07	1.62e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—KRAS—breast cancer	6.56e-07	1.55e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—KRAS—breast cancer	6.48e-07	1.53e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—PIK3CA—breast cancer	6.03e-07	1.42e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—PIK3CA—breast cancer	5.95e-07	1.4e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—TP53—breast cancer	5.83e-07	1.38e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—TP53—breast cancer	5.76e-07	1.36e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—HRAS—breast cancer	5.58e-07	1.32e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—HRAS—breast cancer	5.5e-07	1.3e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—IL6—breast cancer	5.34e-07	1.26e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—IL6—breast cancer	5.27e-07	1.24e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—AKT1—breast cancer	4.92e-07	1.16e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—AKT1—breast cancer	4.86e-07	1.15e-05	CbGpPWpGaD
